Understanding how specific mutations in a protein affect ovarian cancer
Impact of pathogenic missense mutations on the ARID domain of ARID1a
This study is looking at how certain changes in the ARID1a protein might affect its job in keeping cells healthy, which could help us understand more about how ovarian cancer develops and lead to better treatments for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clemson University NIH-funded |
| Lab location | 1 site (Clemson, United States) |
| Project ID | NIH-10654137 on NIH RePORTER |
What this research studies
This research investigates the effects of pathogenic missense mutations in the ARID1a protein, which plays a crucial role in regulating gene activity and maintaining cell health. By analyzing how these mutations impact the protein's stability and its ability to bind DNA, the research aims to uncover the subtle mechanisms that contribute to ovarian cancer development. The approach involves detailed modeling and bioinformatics techniques to predict the consequences of these mutations on cellular functions. Ultimately, this work seeks to provide insights that could lead to improved understanding and treatment options for ovarian cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ovarian cancer, particularly those with known ARID1a mutations.
Not a fit: Patients without ovarian cancer or those whose tumors do not involve ARID1a mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and targeted therapies for ovarian cancer patients.
How similar studies have performed: Previous research has shown that understanding mutations in tumor suppressor genes can lead to significant advancements in cancer treatment, suggesting this approach has potential for success.
Where this research is happening
Clemson, United States
- Clemson University — Clemson, United States (Active)
Researchers
- Principal investigator: Sanabria, Hugo — Clemson University
- Study coordinator: Sanabria, Hugo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.